含质子泵抑制剂、铋剂、四环素和左氧氟沙星的十日四联疗法在幽门螺杆菌感染二线治疗中比标准左氧氟沙星三联疗法更有效:一项随机对照试验
这项随机对照试验在一线治疗失败的幽门螺杆菌感染者中比较了埃索美拉唑-铋剂-四环素-左氧氟沙星四联疗法(TL四联)与埃索美拉唑-阿莫西林-左氧氟沙星三联疗法(AL三联)的10天疗效,中期分析后停止。TL四联组49/50(98.0%)根除成功,AL三联组36/52(69.2%)根除成功,意向性分析显示TL四联根除率显著更高(差值28.8%,95%CI 15.7%至41.9%,P<0.001)。
要点
- TL四联组根除率98.0%(49/50),AL三联组69.2%(36/52),意向性分析差值28.8%(95%CI 15.7%-41.9%,P<0.001)。
- 符合方案分析结果相似:TL四联组97.8% vs AL三联组68.6%(P<0.001)。
- 总体不良事件发生率两组相当(22.0% vs 11.5%),服药依从性相似(90.0% vs 98.1%)。
核心结论
- 十日PPI-铋剂-四环素-左氧氟沙星四联疗法是标准三联或非铋剂四联疗法失败后幽门螺杆菌感染补救治疗的良好选择。
研究设计与样本
- 随机对照试验,连续纳入一线治疗失败的幽门螺杆菌感染者,随机分配接受TL四联或AL三联10天治疗,治疗结束6周后评估幽门螺杆菌状态。
- 研究在中期分析后停止;TL四联组50例,AL三联组52例。
主要发现
- TL四联组49/50(98.0%)根除成功,AL三联组36/52(69.2%)根除成功。
- 意向性分析显示TL四联根除率显著高于AL三联(差值28.8%,95%CI 15.7%至41.9%,P<0.001)。
- 符合方案分析结果相似:TL四联组97.8% vs AL三联组68.6%(P<0.001)。
- 两组总体不良事件发生率相当(22.0% vs 11.5%),服药依从性相似(90.0% vs 98.1%)。
- 亚组分析显示,在标准三联疗法失败的患者中TL四联优于AL三联(100% vs 75.0%,P=0.010),在非铋剂四联疗法失败的患者中亦优于AL三联(95.0% vs 52.6%,P=0.003)。
关键数值与推荐
- TL四联方案:埃索美拉唑40mg bid、铋剂120mg qid、四环素500mg qid、左氧氟沙星500mg qd,疗程10天。
- AL三联方案:埃索美拉唑40mg bid、阿莫西林500mg qid、左氧氟沙星500mg qd,疗程10天。
临床怎么用
- 作者认为,对于标准三联或非铋剂四联疗法失败的幽门螺杆菌感染,十日PPI-铋剂-四环素-左氧氟沙星四联疗法是良好的补救治疗选择。
局限性
- 研究在中期分析后停止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Proton pump inhibitor (PPI)-amoxicillin-fluoroquinolone triple therapy is recommended as a second-line treatment of Helicobacter pylori infection in the Maastricht V/Florence Consensus Report. However, the eradication rate of this standard salvage treatment is suboptimal. The objective of this study is to compare the efficacy of esomeprazole-bismuth-tetracycline-levofloxacin therapy (TL quadruple therapy) and esomeprazole-amoxicillin-levofloxacin triple therapy (AL triple therapy) in rescue treatment for H. pylori infection. METHODS: Consecutive H. pylori-infected subjects after failure of first-line therapies were randomly allocated to receive either TL quadruple therapy (esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.) or AL triple therapy (esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.) for 10 days. H. pylori status was assessed 6 weeks after the end of treatment. RESULTS: The study was stopped after an interim analysis. Of 50 patients in the TL quadruple therapy, 49 (98.0%) had successful eradication of H. pylori infection. Cure of H. pylori infection was achieved in 36 of 52 patients (69.2%) receiving AL triple therapy. Intention-to-treat analysis demonstrated that TL quadruple therapy achieved a markedly higher eradication rate than AL triple therapy (difference: 28.8%; 95% confidence interval: 15.7% to 41.9%; P<0.001). Per-protocol analysis yielded a similar result (97.8% vs. 68.6%; P<0.001). The two treatment groups exhibited comparable frequencies of overall adverse events (22.0% vs. 11.5%) and drug compliance (90.0% vs. 98.1%). The subgroup analysis showed that TL quadruple therapy was superior to AL triple therapy in patients with failure of either standard triple therapy (100% vs. 75.0%; P=0.010) or non-bismuth quadruple therapy (95.0% vs. 52.6%; P=0.003). CONCLUSIONS: Ten-day PPI-bismuth-tetracycline-levofloxacin quadruple therapy is a good option for rescue treatment of H. pylori infection following failure of standard triple or non-bismuth quadruple therapy.
引用
- Hsu PI, Tsai FW, Kao SS, et al. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial. Am J Gastroenterol. 2017. PMID: 28719592. doi:10.1038/ajg.2017.195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。